antibacterial agent 18

Antibacterial agent 18, a multi-arm AIE molecule, demonstrates efficacy against both Gram-positive and Gram-negative bacteria. Antibacterial agent 18 functions by conjugating with the cell wall of bacteria with rigid arm configuration, thereby interfering with the sugar and peptide processes essential for cell wall turning. This mechanism inhibits or eradicates bacterial growth[1].

4-(4,5-dibromo-6-oxo-1,6-dihydropyridazin-1-yl)benzene-1-sulfonamide is a sulfonamide derivative used in the synthesis of building blocks for various supramolecular structures such as metal-organic skeletons and coordination polymers. It has antiproliferative activity against a variety of tumor cell lines.

Antibacterial agent 132 showed antimicrobial activity against C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) with MIC90 values of <0.06 μg mL and 62.50 μg mL, respectively. Antibacterial agent 132 inhibited aromatase enzyme with IC50 of 0.047 μM.

(2S)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide is a LpxC inhibitor with IC50 >95.2 nM.

Antibacterial agent 27 has potent anti-Candida activity.

Compound 5k (Antiproliferative Agent-18) is an antiproliferative agent that exhibits moderate antibacterial and antifungal activities [1].

Antibacterial agent 52 (example 18) is an antibacterial agent.

Antibacterial agent 66 (Compound 6q) is a trifluoromethylpyridine 1,3,4-oxadiazole derivative active against Xanthomonas oryzae pv. oryzae (Xoo) (EC50: 7.2 μg/mL).

Antibacterial agent 37 is an effective antimicrobial compound. It holds potential as a valuable tool for researching bacterial infections.

Antibacterial Agent 42 demonstrates potent antibacterial activity by effectively reducing the Minimum Inhibitory Concentration (MIC) of the broad-spectrum antibacterial agent Ceftazidime.

Antibacterial agent 30 exhibits remarkable in vitro activity against Xoo, as evidenced by its EC50 value of 1.9 μg/mL.

Antibacterial agent 57 (example 25) is an antibacterial agent.

Antibacterial agent 88 is an effective antibacterial agent against B. subtilis (MIC: 4 μg/ml) with MIC values of ≤0.0156 μg/mL for MRSA, MRSE and S. aureus.

Antibacterial agent 92, a triple-site aminoacyl-tRNA synthetase (aaRS) inhibitor, demonstrates a potent antibacterial effect by inhibiting Salmonella enterica threonyl-tRNA synthetase (SeThrRS) with an IC50 of 0.58 μM.

Antibacterial agent 131 is a compound with antibacterial properties.

Aztreonam-siderophore conjugate 63 is an antibacterial agent that exhibits efficacy against Gram-negative bacteria through the linkage of aztreonam to a siderophore mimetic.

Compound A11 (Antibacterial agent 86) exhibits the highest bacteriostatic activity against methicillin-resistant S. aureus, with minimum inhibitory concentration (MIC) values reaching as low as 0.00191 μg/mL. This efficacy is 162 and 32 times greater than the commercial antibiotics tiamulin and retapamulin, respectively [1].

Antibacterial Agent 136 (Compound 3), an oxadiazolone antibiotic, exhibits high antibacterial potency against Methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) 50 value of 0.8 μM [1].

Antibacterial agent 116, a benzophenone-containing salicylanilide compound, exhibits potent antibacterial activity by inhibiting peptidoglycan formation. It is employed as a photoaffinity probe to label Acinetobacter baumannii penicillin-binding protein (PBP1b), thereby blocking the propagation pathway and disrupting the growth of the peptidoglycan chain.

Antibacterial Agent 123 (Compound 111) serves as an effective membrane-disrupting agent targeting antibiotic-resistant Gram-positive bacteria [1].

Antibacterial Agent 128, a siderophore analog-Ciprofloxacin (Ciprofloxacin) conjugate connected via a cleavable linker, demonstrates effective antibiotic properties. Specifically, it exhibits activity against P. aeruginosa and B. pseudomallei, with Minimum Inhibitory Concentration (MIC) values ranging from 0.25 to 64 μg/mL and 1 to 32 μg/mL, respectively [1].

Antibacterial agent 46, serves as a potent antibacterial compound. With its versatile properties, this agent demonstrates considerable potential for supporting research on bacterial infections.

Antibacterial agent 101 exhibited antibacterial and antifungal effects (MIC=4-32 μg/mL).

Antibacterial agent 98 (compound g37) is an effective oral antibacterial agent that inhibits the ATPase activity of Gyrase B and weakens the DNA super-helix of S. aureus. Notably, it does not induce the development of MRSA (methicillin-resistant Staphylococcus aureus) resistance.

Antibacterial agent 75 (compound 24) exhibits antibacterial properties and notably re-sensitizes VRSA (Vancomycin-Resistant Staphylococcus aureus) strains to vancomycin, as reported in reference [1].

Antibacterial Agent 33, a potent antibacterial compound, effectively decreases the minimum inhibitory concentration (MIC) of Ceftazidime, another antibacterial agent.

Antibacterial agent 80 (compound 20) demonstrates antibacterial activity [1].

Antibacterial agent 32 exhibits potent antimicrobial activity against E. coli strains NCTC 13351, M 50, and 7 MP, with minimum inhibitory concentration (MIC) values of 1 mcg/mL, 2 mcg/mL, and 8 mcg/mL, respectively (WO2013030733A1, example 43).

Antibacterial agent 62 is a novel redox cycle anti-tuberculosis compound exhibiting significant bactericidal activity against both growing and phenotypically resistant non-growing (nutrient deficient) bacteria.

Antibacterial agent 55 [example 21] is an antibacterial agent.

Antibacterial agent 48 is an antimicrobial agent that reduces the MIC of the antimicrobial agent Ceftazidime.

Antibacterial agent 94 (compound 5b) is a highly effective antibacterial agent demonstrating strong activity against various bacterial strains, notably eradicating MRSA persisters and highlighting its therapeutic potential. Its mechanism of action involves interference with the bacterial membrane and disruption of the phosphatidylglycerol (PG) synthesis pathway [1].

Compound 18 (compound 8b), a nitrofuran derivative, exhibits potent in vitro trypanocidal activity, with an IC50 value of 0.03 μM [1].

Antibacterial agent 162 trifluoromethanesulfonate (compound 7), a dual-function molecule, demonstrates potent inhibitory effects on Staphylococcus aureus, including MRSA strains, and exhibits antiproliferative activity against colon cancer and non-small cell lung cancer cells. This compound is applicable in both anticancer and antibacterial research [1].

Compound 6 (Antibacterial agent 161, trifluoromethanesulfonate) exhibits antibacterial properties and demonstrates significant antiproliferative effects against colon cancer and non-small cell lung cancer [1].

Antibacterial Agent 160 is a potent antibacterial agent that rapidly eradicates bacteria and inhibits the formation of bacterial biofilms. It disrupts the normal functioning of DNA, resulting in cellular death [1].

Antibacterial Agent 156 (Compound 57), a bactericidal that selectively targets C. difficile cell-wall synthesis, demonstrates potent activity with minimal inhibitory concentrations of 0.5 μg/mL for MIMIC50 (101 strains) and 1 μg/mL for MIC90 (101 strains) [1].

Antiparasitic agent-18 (compound 3a) exhibits potent and selective antiprotozoal activity, effectively inhibiting T. brucei (EC50 = 0.4 µM), T. cruzi (EC50 = 0.21 µM), and L. donovani (EC50 = 0.26 µM) [1].

Compound 6d (Antibacterial agent 159) is an antibiotic effective against impetigo and Clostridium difficile infection (CDI), with no observed recurrence for CDI and minimal impact on the beneficial gut microbiome [1].

Antibacterial agent 153, a broad-spectrum agent, eradicates bacteria by targeting their cell membranes and is employed in research on bacterial infections [1].

Antibacterial agent 73 (compound 7a) exhibits antitubercular, antibacterial, and antifungal activities, with promising antitubercular activity (MIC of 0.65 μg mL) against Mtb H37Rv, and also demonstrates cytotoxicity in MCF-7 breast cancer cell lines (IC 50 of 8.20 μM) [1].

Antibacterial agent 90 (6n) is a pleuromutilin derivative with antibacterial activity against Gram-positive pathogens (GPPs) and Mycoplasma pneumoniae.

Antibacterial agent 59 (example 24) is an antibacterial compound.

Antibacterial Agent 58 (AA58) is a potent antibacterial compound that effectively reduces the minimum inhibitory concentration (MIC) value of Ceftazidime, another antibacterial agent.

Antibacterial Agent 47 demonstrates potent antibacterial activity as an adjunct therapy to parenteral antibiotic Ceftazidime. By effectively reducing the minimum inhibitory concentration (MIC) of Ceftazidime, Antibacterial Agent 47 acts as a highly promising antimicrobial agent, thereby enhancing the overall efficacy of the treatment.

Antibacterial agent 60 is a potent compound that effectively reduces the minimum inhibitory concentration (MIC) of Ceftazidime, an antibacterial agent.